Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:31:39 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:MBRX - MOLECULIN BIOTECH INC - http://moleculin.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MBRX - Q0.14.10·5.250.15.01+0.245.046.22153684.80  5.25  4.8015.75  4.2816:00:01Apr 2515 min RT 2¢

Recent Trades - Last 10 of 368
Time ETExPriceChangeVolume
16:00:01Q5.140.5147
16:00:01Q5.140.516
16:00:01Q5.140.515
15:59:46Q5.010.24100
15:59:36Q5.0750.305300
15:59:30Q5.010.3816
15:59:24Q5.010.387
15:58:58Q4.970.348
15:58:22Q4.970.348
15:58:10Q5.060.4323

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-25 09:48U:MBRXNews ReleaseMoleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
2024-04-18 08:30U:MBRXNews ReleaseEuropean Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
2024-04-10 08:30U:MBRXNews ReleaseMoleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
2024-03-28 10:45U:MBRXNews ReleaseMoleculin to Present at the MedInvest Biotech & Pharma Investor Conference
2024-03-27 09:25U:MBRXNews ReleaseMoleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
2024-03-27 09:05U:MBRXNews ReleaseMoleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
2024-03-25 07:30U:MBRXNews ReleaseMoleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
2024-03-22 16:05U:MBRXNews ReleaseMoleculin Reports Full Year 2023 Financial Results
2024-03-20 07:30U:MBRXNews ReleaseMoleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
2024-03-19 16:30U:MBRXNews ReleaseMoleculin Announces Reverse Stock Split
2024-03-12 09:05U:MBRXNews ReleaseMoleculin to Present at the 36th Annual ROTH Conference
2024-01-24 08:50U:MBRXNews ReleaseMoleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
2023-12-20 21:16U:MBRXNews ReleaseMoleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
2023-12-11 08:50U:MBRXNews ReleaseMoleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting
2023-11-13 08:05U:MBRXNews ReleaseMoleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
2023-11-13 08:00U:MBRXNews ReleaseMoleculin Reports Third Quarter 2023 Financial Results
2023-11-07 08:45U:MBRXNews ReleaseMoleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
2023-11-06 08:35U:MBRXNews ReleaseMoleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases
2023-10-11 09:05U:MBRXNews ReleaseMoleculin to Participate in the Virtual Investor Ask the CEO Conference
2023-10-02 08:40U:MBRXNews ReleaseMoleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)